Document Detail

Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention.
MedLine Citation:
PMID:  22220931     Owner:  NLM     Status:  Publisher    
1. Inflammation is central to the pathogenesis of acute coronary syndrome (ACS) and is associated with adverse clinical outcomes after percutaneous coronary intervention (PCI). Recent in vitro work from us and others has shown the anti-inflammatory effect of berberine, a main component of the traditional Chinese medicine umbellatine. We further tested whether berberine had beneficial effect on ACS patients following PCI. 2. 130 ACS patients undergoing PCI were recruited in this study. 61 patients were treated with berberine (300mg, 3 times a day, for 30 days) in addition to standard therapy while the remaining patients received standard therapy alone. Circulating inflammatory markers were measured by ELISA assays and serum lipid profiles were measured by routine chemical assays. 3. In berberine-treated group, matrix metalloproteinase-9 (MMP-9), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), C-reactive protein, interleukin-6 and monocyte chemoattractant protein-1 were significantly reduced relative to baseline values (P<0.05 or <0.001). Furthermore, the changes in MMP-9, ICAM-1 and VCAM-1 between baseline and after 1 month of treatment was significantly different for the two groups (P<0.05). Berberine induced a slightly greater reduction (but not statistically significant) in low-density lipoprotein cholesterol and triglycerides than standard therapy alone, without affecting high-density lipoprotein cholesterol. No severe adverse effects of berberine were observed. 4. These results, for the first time, provide clinical evidence of the anti-inflammatory action of berberine in ACS patients following PCI. Berberine may become a potential adjunctive therapy to further improve clinical outcomes via its anti-inflammatory effect in ACS patients. © 2012 The Authors Clinical and Experimental Pharmacology and Physiology© 2012 Blackwell Publishing Asia Pty Ltd.
S Meng; L-S Wang; Z-Q Huang; Q Zhou; Y-G Sun; J-T Cao; Y-G Li; C-Q Wang
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-3
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology     Volume:  -     ISSN:  1440-1681     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0425076     Medline TA:  Clin Exp Pharmacol Physiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. Clinical and Experimental Pharmacology and Physiology © 2012 Blackwell Publishing Asia Pty Ltd.
Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai, China Department of Laboratory Medicine, Shanghai Ninth People's Hospital Affiliated Shanghai Jiaotong University, School of Medicine, Shanghai, China Department of Cardiology, The First Affiliated Hospital, Wenzhou Medical College, Wenzhou, China Department of Cardiology, Shanghai Ninth People's Hospital Affiliated Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Frontal EEG asymmetry moderates the effects of stressful life events on internalizing symptoms in ch...
Next Document:  Groundwater Biofilm Dynamics Grown In Situ Along a Nutrient Gradient.